Cargando…

Detection of cytokeratin-19 mRNA-positive cells in the peripheral blood and bone marrow of patients with operable breast cancer

BACKGROUND: To compare detection rates and evaluate the clinical relevance of cytokeratin-19 (CK-19) mRNA-positive cells in the peripheral blood (circulating tumour cells, CTCs) and bone marrow (disseminated tumour cells; DTCs) of patients with early breast cancer. METHODS: Paired samples of periphe...

Descripción completa

Detalles Bibliográficos
Autores principales:	Daskalaki, A, Agelaki, S, Perraki, M, Apostolaki, S, Xenidis, N, Stathopoulos, E, Kontopodis, E, Hatzidaki, D, Mavroudis, D, Georgoulias, V
Formato:	Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2009
Materias:	Clinical Study
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2736820/ https://www.ncbi.nlm.nih.gov/pubmed/19623181 http://dx.doi.org/10.1038/sj.bjc.6605183

Ejemplares similares

Cytokeratin-19 mRNA-positive circulating tumor cells during follow-up of patients with operable breast cancer: prognostic relevance for late relapse
por: Saloustros, Emmanouil, et al.
Publicado: (2011)

Differential effect of adjuvant taxane-based and taxane-free chemotherapy regimens on the CK-19 mRNA-positive circulating tumour cells in patients with early breast cancer
por: Xenidis, N, et al.
Publicado: (2013)

Clinical relevance of circulating CK-19mRNA-positive tumour cells before front-line treatment in patients with metastatic breast cancer
por: Androulakis, N, et al.
Publicado: (2012)

Ribonucleotide reductase subunits M1 and M2 mRNA expression levels and clinical outcome of lung adenocarcinoma patients treated with docetaxel/gemcitabine
por: Souglakos, J, et al.
Publicado: (2008)

Detection of circulating tumour cells before and following adjuvant chemotherapy and long-term prognosis of early breast cancer
por: Matikas, Alexios, et al.
Publicado: (2022)

Efficacy of Lapatinib in Therapy-Resistant HER2-Positive Circulating Tumor Cells in Metastatic Breast Cancer
por: Agelaki, Sofia, et al.
Publicado: (2015)

Cytokeratin-positive cells in bone marrow for identifying distant micrometastasis of gastric cancer.
por: Maehara, Y., et al.
Publicado: (1996)

Central nervous system relapse in patients with breast cancer is associated with advanced stages, with the presence of circulating occult tumor cells and with the HER2/neu status
por: Souglakos, John, et al.
Publicado: (2006)

Cytokeratin 20 mRNA in peripheral venous blood of colorectal carcinoma patients.
por: Funaki, N. O., et al.
Publicado: (1998)

Correlation of BRCA1, TXR1 and TSP1 mRNA expression with treatment outcome to docetaxel-based first-line chemotherapy in patients with advanced/metastatic non-small-cell lung cancer
por: Papadaki, C, et al.
Publicado: (2011)

Phosphorylated EGFR and PI3K/Akt signaling kinases are expressed in circulating tumor cells of breast cancer patients
por: Kallergi, Galatea, et al.
Publicado: (2008)

Cytokeratin phosphorylation, cytokeratin filament severing and the solubilization of the maternal mRNA Vg1
Publicado: (1991)

Prognostic Significance of Occult Bone Marrow Micrometastases of Breast Cancer Detected by Quantitative Polymerase Chain Reaction for Cytokeratin 19 mRNA
por: Ikeda, Noriko, et al.
Publicado: (2000)

The presence of bone marrow cytokeratin-immunoreactive cells does not predict outcome in gastric cancer patients
por: de Manzoni, G, et al.
Publicado: (2002)

Epithelial to mesenchymal transition markers expressed in circulating tumour cells of early and metastatic breast cancer patients
por: Kallergi, Galatea, et al.
Publicado: (2011)

Sequential vs concurrent epirubicin and docetaxel as adjuvant chemotherapy for high-risk, node-negative, early breast cancer: an interim analysis of a randomised phase III study from the Hellenic Oncology Research Group
por: Mavroudis, Dimitrios, et al.
Publicado: (2017)

Expression of truncated human epidermal growth factor receptor 2 on circulating tumor cells of breast cancer patients
por: Kallergi, Galatea, et al.
Publicado: (2015)

CD44(+) cytokeratin-positive tumor cells in blood and bone marrow are associated with poor prognosis of patients with gastric cancer
por: Szczepanik, Antoni, et al.
Publicado: (2018)

A triplet combination with irinotecan (CPT-11), oxaliplatin (LOHP), continuous infusion 5-fluorouracil and leucovorin (FOLFOXIRI) plus cetuximab as first-line treatment in KRAS wt, metastatic colorectal cancer: a pilot phase II trial
por: Saridaki, Z, et al.
Publicado: (2012)

Comparison of EGFR and K-RAS gene status between primary tumours and corresponding metastases in NSCLC
por: Kalikaki, A, et al.
Publicado: (2008)

Salvage chemotherapy with high-dose leucovorin (LV) and 48-hour continuous infusion (CI) of 5-fluorouracil (5-FU) in combination with conventional doses of cyclophosphamide (CPM) in patients with metastatic breast cancer (MBC) pretreated with anthracycline and taxanes
por: Kalbakis, K, et al.
Publicado: (2001)

Cytokeratin-positive cells in the bone marrow from patients with pancreatic, periampullary malignancy and benign pancreatic disease show no prognostic information
por: Hugenschmidt, Harald, et al.
Publicado: (2020)

Validation of droplet digital PCR for cytokeratin 19 mRNA detection in canine peripheral blood and mammary gland
por: Tanvetthayanont, Potsawat, et al.
Publicado: (2022)

BRAF mutations, microsatellite instability status and cyclin D1 expression predict metastatic colorectal patients’ outcome
por: Saridaki, Z, et al.
Publicado: (2010)

Variable expression levels of keratin and vimentin reveal differential EMT status of circulating tumor cells and correlation with clinical characteristics and outcome of patients with metastatic breast cancer
por: Polioudaki, Hara, et al.
Publicado: (2015)

Detection of KRAS Exon 2 Mutations in Circulating Tumor Cells Isolated by the ISET System from Patients with RAS Wild Type Metastatic Colorectal Cancer()
por: Matikas, Alexios, et al.
Publicado: (2017)

Clinical challenges in the molecular characterization of circulating tumour cells in breast cancer
por: Lianidou, E S, et al.
Publicado: (2013)

A randomized phase III study of the docetaxel/carboplatin combination versus docetaxel single-agent as second line treatment for patients with advanced/metastatic Non-Small Cell Lung Cancer
por: Pallis, Athanasios G, et al.
Publicado: (2010)

Cytokeratin 20-positive hepatocellular carcinoma
por: Fanni, D., et al.
Publicado: (2009)

Co-expression of putative stemness and epithelial-to-mesenchymal transition markers on single circulating tumour cells from patients with early and metastatic breast cancer
por: Papadaki, Maria A, et al.
Publicado: (2014)

Evaluation of proliferation and apoptosis markers in circulating tumor cells of women with early breast cancer who are candidates for tumor dormancy
por: Spiliotaki, Maria, et al.
Publicado: (2014)

Hypoxia-inducible factor-1α and vascular endothelial growth factor expression in circulating tumor cells of breast cancer patients
por: Kallergi, Galatea, et al.
Publicado: (2009)

Expression of insulin‐like growth factor‐1 receptor in circulating tumor cells of patients with breast cancer is associated with patient outcomes
por: Spiliotaki, Maria, et al.
Publicado: (2017)

Assessment of the Efficacy and Clinical Utility of Different Circulating Tumor Cell (CTC) Detection Assays in Patients with Chemotherapy-Naïve Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
por: Papadaki, Maria A., et al.
Publicado: (2021)

A multicentre phase II trial of cabazitaxel in patients with advanced non-small-cell lung cancer progressing after docetaxel-based chemotherapy
por: Kotsakis, A, et al.
Publicado: (2016)

KRAS Genotypic Changes of Circulating Tumor Cells during Treatment of Patients with Metastatic Colorectal Cancer
por: Kalikaki, Aristea, et al.
Publicado: (2014)

A dose escalation and pharmacokinetic study of biweekly pegylated liposomal doxorubicin, paclitaxel and gemcitabine in patients with advanced solid tumours
por: Bozionelou, V, et al.
Publicado: (2007)

‘Classical’ but not ‘other’ mutations of EGFR kinase domain are associated with clinical outcome in gefitinib-treated patients with non-small cell lung cancer
por: Pallis, A G, et al.
Publicado: (2007)

Aberrant Cytokeratin 20 mRNA Expression in Peripheral Blood and Lymph Nodes Indicates Micrometastasis and Poor Prognosis in Patients With Gastric Carcinoma
por: You, Xiaolan, et al.
Publicado: (2019)

Haematogenous cytokeratin 20 mRNA as a predictive marker for recurrence in oral cancer patients
por: Kawamata, H, et al.
Publicado: (1999)

Cannot write session to /tmp/vufind_sessions/sess_u2oa3qro7fv0pqrc002eo18v2o